Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Intern Emerg Med. 2023 Apr;18(3):821-830. doi: 10.1007/s11739-023-03231-w. Epub 2023 Feb 28.
More than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations.
全球已接种超过 115 亿剂 COVID-19 疫苗。虽然严重感染的疫苗有效性据报道为 89.0%,但突破性感染很常见,并且可能导致脆弱人群出现严重后果。我们在意大利一家三级医院对 2021 年 7 月至 2022 年 1 月期间收治的 420 名 COVID-19 住院患者进行了一项真实世界的观察性研究。我们收集了患者的疫苗接种和 SARS-CoV-2 血清学状态、SARS-CoV-2 治疗、氧支持、重症监护 (ICU) 和亚重症监护 (sub-ICU) 入院、住院时间 (LoS) 和院内死亡率。在研究期间,172 名接种疫苗和 248 名未接种疫苗的患者入院。接种组 (Vg) 的 Charlson 合并症指数明显高于未接种组 (UVg),但在院内死亡率、LoS 或 ICU 和 sub-ICU 入院方面无统计学差异。在 Vg 中,86.18%的患者检测到抗-S 抗体 (血清阳性)。接种疫苗但血清阴性患者的院内死亡率明显高于接种疫苗但血清阳性患者 (33.33%比 10.69%,p=0.0055):特别是在 45-69 岁人群中,接种疫苗但血清阴性组的死亡率更高,而在≥70 岁的患者中则相当。考虑到 Vg 年龄较大且合并症较多,在 Vg 和 UVg 之间,无论在结局方面都没有差异。与其他最近的观察结果一致,血清阴性的接种疫苗患者死亡率更高。初级预防和早期治疗是必要的,特别是针对老年和免疫抑制人群。